688 related articles for article (PubMed ID: 24036844)
1. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?
Petta V; Gkiozos I; Strimpakos A; Syrigos K
Cancer Chemother Pharmacol; 2013 Nov; 72(5):935-52. PubMed ID: 24036844
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
3. The potential of histone deacetylase inhibitors in lung cancer.
Aparicio A
Clin Lung Cancer; 2006 Mar; 7(5):309-12. PubMed ID: 16640801
[TBL] [Abstract][Full Text] [Related]
4. HDAC inhibitors for the treatment of cancer.
Secrist JP; Zhou X; Richon VM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of histone deacetylases.
Huang Y; Shaw PG; Davidson NE
Methods Mol Biol; 2011; 791():297-311. PubMed ID: 21913088
[TBL] [Abstract][Full Text] [Related]
6. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
7. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
Richon VM
Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
[TBL] [Abstract][Full Text] [Related]
8. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
Damaskos C; Garmpis N; Valsami S; Kontos M; Spartalis E; Kalampokas T; Kalampokas E; Athanasiou A; Moris D; Daskalopoulou A; Davakis S; Tsourouflis G; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Anticancer Res; 2017 Jan; 37(1):35-46. PubMed ID: 28011471
[TBL] [Abstract][Full Text] [Related]
9. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
10. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
Yoshida M; Shimazu T; Matsuyama A
Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylases and their inhibitors: new implications for asthma and chronic respiratory conditions.
Royce SG; Karagiannis TC
Curr Opin Allergy Clin Immunol; 2014 Feb; 14(1):44-8. PubMed ID: 24322009
[TBL] [Abstract][Full Text] [Related]
12. HDAC inhibitors: a potential new category of anti-tumor agents.
Pan LN; Lu J; Huang B
Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
[TBL] [Abstract][Full Text] [Related]
13. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
Rangwala S; Zhang C; Duvic M
Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Carew JS; Giles FJ; Nawrocki ST
Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
[TBL] [Abstract][Full Text] [Related]
15. Potential role of HDAC inhibitors in cancer therapy: insights into oral squamous cell carcinoma.
Iglesias-Linares A; Yañez-Vico RM; González-Moles MA
Oral Oncol; 2010 May; 46(5):323-9. PubMed ID: 20207580
[TBL] [Abstract][Full Text] [Related]
16. Targeting histone deacetylase in thyroid cancer.
Russo D; Durante C; Bulotta S; Puppin C; Puxeddu E; Filetti S; Damante G
Expert Opin Ther Targets; 2013 Feb; 17(2):179-93. PubMed ID: 23234477
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors in cancer therapy.
Lane AA; Chabner BA
J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
[TBL] [Abstract][Full Text] [Related]
19. Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.
Zafar SF; Nagaraju GP; El-Rayes B
Expert Opin Ther Targets; 2012 Jul; 16(7):707-18. PubMed ID: 22621256
[TBL] [Abstract][Full Text] [Related]
20. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
Singh AK; Bishayee A; Pandey AK
Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]